Context acquired CT-95, a potentially first-in-class mesothelin (“MSLN”) x CD3 bispecific antibody. This is the second clinical-stage T cell engager for solid tumors in our pipeline. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. Learn more here. https://lnkd.in/gVu_g6zw
Context Therapeutics
Biotechnology Research
Philadelphia, Pennsylvania 2,682 followers
Advancing T Cell Engagers for Solid Tumors
About us
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.
- Website
-
http://www.contexttherapeutics.com
External link for Context Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Public Company
- Founded
- 2015
- Specialties
- Oncology and Bispecific Antibody
Locations
-
Primary
Get directions
2001 Market Street
Suite 3915, Unit 15
Philadelphia, Pennsylvania 19103, US
Employees at Context Therapeutics
Updates
-
Context Therapeutics is growing! Learn more @ https://lnkd.in/ekwAzDu4
-
-
Our CEO, Martin Lehr, will present at the Piper Sandler 36th Annual Healthcare Conference on December 4th at 11:00am ET. #PiperSandler, #oncology
-
-
Today, the Context Therapeutics team discussed the selection of a first-in-human dose for CTIM-76, a Claudin 6 x CD3 bispecific antibody. You can access the poster here: https://lnkd.in/erYZ9tRH #SITC2024, #oncology
-
-
Our CEO, Martin Lehr, will participate in a fireside chat at the 2024 Guggenheim Healthcare Conference on November 11th at 3pm ET. Access the live webcast via: https://lnkd.in/gAYJF45X #guggenheim, #oncology
-
-
Context Therapeutics reposted this
Context Therapeutics and BioAtla, Inc. Announce Exclusive Worldwide License Agreement to Develop and Commercialize CT-202 (formerly BA3362), a Nectin-4 x CD3 T Cell Engaging Antibody. - Context to obtain exclusive development and commercialization rights to CT-202 - BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales - Context anticipated IND filing for CT-202 in mid-2026 https://lnkd.in/eH2H2Whi
-
-
Context Therapeutics and BioAtla, Inc. Announce Exclusive Worldwide License Agreement to Develop and Commercialize CT-202 (formerly BA3362), a Nectin-4 x CD3 T Cell Engaging Antibody. - Context to obtain exclusive development and commercialization rights to CT-202 - BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales - Context anticipated IND filing for CT-202 in mid-2026 https://lnkd.in/eH2H2Whi
-